Allergy Shots and Asthma: Cochrane NNT 3, FEV1 Threshold, and PAT Prevention
Allergy shots reduce allergic-asthma symptoms by roughly a third and medication use by roughly a third — NNT approximately 3 per the Cochrane 2010 review (Abramson, 88 trials) — but severe or uncontrolled asthma (FEV1 persistently less than 70% predicted) is a contraindication. Most SCIT fatalities have occurred in patients with labile uncontrolled asthma. Three years of pediatric pollen SCIT in monosensitized children roughly halves the development of asthma at 10-year follow-up (PAT study, Jacobsen 2007, OR 4.6).
6 peer-reviewed sources
Allergic asthma with identifiable IgE-mediated triggers is an indication for SCIT per Cox 2011 PP3. Cochrane NNT is approximately 3 to prevent asthma deterioration. FEV1 below 70% predicted or recent severe exacerbation is a contraindication.
The essentials
Allergy shots reduce allergic-asthma symptoms by roughly a third and medication use by roughly a third — NNT approximately 3 per the Cochrane 2010 review — but severe or uncontrolled asthma (FEV1 persistently less than 70% predicted) is a contraindication because most SCIT fatalities have occurred in patients with labile uncontrolled asthma.
The indication is specific: allergic asthma with an identifiable IgE-mediated trigger (dust mite, animal dander, mold, pollen). SCIT is NOT indicated for non-allergic asthma (also called intrinsic or occupational non-IgE asthma). A board-certified allergist confirms IgE sensitization through skin-prick testing or specific IgE blood testing before prescribing the extract.
Before starting allergy shots in an allergic-asthma patient, Curex's at-home IgE testing with board-certified allergist review identifies which IgE-mediated trigger drives symptoms — single-allergen sensitization (often manageable with Odactra, the FDA-approved house-dust-mite SLIT tablet) versus polysensitization (multi-allergen SCIT territory).
The Cochrane evidence: Abramson MJ, Puy RM, Weiner JM, 'Injection allergen immunotherapy for asthma,' Cochrane Database Syst Rev 2010;(8):CD001186 (DOI 10.1002/14651858.CD001186.pub2) — 88 trials, significant symptom score and medication use reductions, NNT approximately 3 to avoid asthma symptom deterioration and approximately 5 to avoid medication increase; overall NNT 4 (95% CI 3–6) to avoid one patient requiring increased medication. One systemic reaction (any severity) per 9 treated; one local reaction per 16 treated. The magnitude of benefit was possibly comparable to inhaled corticosteroids in one trial.
The contraindication: severe or poorly controlled asthma is a contraindication per Cox 2011 PP3. The operative markers are FEV1 persistently below 70% predicted despite pharmacotherapy, or a recent severe exacerbation requiring emergency care or systemic corticosteroids. Asthma should be confirmed as controlled before each injection. Many practices assess peak flow pre-injection in unstable asthmatic patients.
Pediatric disease-modifying dimension: the PAT study (Möller C et al., JACI 2002; Jacobsen L et al., Allergy 2007) documented that 3 years of pollen SCIT in monosensitized children aged 6–14 roughly halved the development of asthma at 10-year follow-up. The longitudinal OR for remaining asthma-free was 4.6 (95% CI 1.5–13.7) favoring SCIT. This is a disease-modifying prevention finding — adults receiving SCIT do not gain the same longitudinal asthma-prevention benefit.
Ready to skip the surprise bills?
See if at-home allergy shots fit your allergies — a 2-minute quiz, designed by board-certified allergists, with flat monthly pricing and no clinic visits.
- 4.8/5Patient rating
- $129/moFlat pricing
- 50K+Patients treated
- HSA/FSAEligible
Efficacy by allergen — what the data shows
The Cochrane meta-analysis (Abramson 2010, 88 trials) provides the most comprehensive efficacy estimate for SCIT in allergic asthma: significant reductions in asthma symptom scores, medication use, and allergen-specific bronchial hyperreactivity. NNT approximately 3 to prevent symptom deterioration; NNT approximately 5 to prevent medication increase. The magnitude in one trial was possibly comparable to inhaled corticosteroids.
Same proven results. No clinic visits.
Curex's at-home allergy shots deliver the same allergen desensitization as clinic SCIT — for a flat $129/month, with no clinic visits and no facility fees.
See if at-home shots are right for youSide effects — what to watch for
Asthmatic patients receiving SCIT face higher systemic reaction risk if asthma is inadequately controlled at the time of injection. Surveillance data confirm that most SCIT fatalities have occurred in patients with labile asthma. The mandatory 30-minute observation period is especially critical for asthmatic patients.
Frequently asked questions
Do allergy shots help with asthma?
Yes, when asthma is allergic (IgE-mediated) and the triggering allergen is identifiable. The Cochrane meta-analysis (Abramson MJ et al., Cochrane Database Syst Rev 2010;(8):CD001186) analyzed 88 randomized trials and found that allergen injection immunotherapy significantly reduced asthma symptom scores, asthma medication use, and allergen-specific bronchial hyperreactivity. The number needed to treat (NNT) to prevent asthma symptom deterioration is approximately 3 — a clinically meaningful number. SCIT does not help non-allergic (intrinsic) asthma because it works by building tolerance to the specific IgE-sensitizing allergen, not by broadly reducing airway inflammation.
Is there a contraindication to allergy shots in asthma?
Yes. Severe or poorly controlled asthma is a contraindication to SCIT per the AAAAI/ACAAI Practice Parameter Third Update (Cox et al., JACI 2011). The operative threshold is FEV1 persistently below 70% predicted despite pharmacotherapy, or a recent severe exacerbation requiring emergency care or systemic corticosteroids. This contraindication exists because most SCIT fatalities in AAAAI surveillance (Epstein TG et al., 2013/2014) occurred in patients with labile or uncontrolled asthma. Asthma must be confirmed as controlled before each injection visit — many allergists assess peak flow pre-injection in unstable patients as a safety check.
How effective are allergy shots for asthma compared to inhalers?
The Cochrane review (Abramson 2010) noted that the magnitude of SCIT benefit in allergic asthma was possibly comparable to inhaled corticosteroids in at least one trial — though SCIT and inhaled steroids have different mechanisms and are not directly compared across the full evidence base. The distinctive advantage of SCIT over inhalers is disease modification: SCIT can produce immunological tolerance that reduces allergen-driven asthma for years after the course ends, while inhaled corticosteroids are purely symptomatic. Inhaled corticosteroids do not prevent future asthma exacerbations when discontinued. SCIT does not replace controller inhalers during the build-up phase — both are typically continued concurrently.
Can children with asthma get allergy shots?
Yes, with the same contraindication caveat: pediatric asthma must be mild-to-moderate and well-controlled (FEV1 at or above 70% predicted) before starting SCIT. For monosensitized children with both allergic rhinitis and asthma, the PAT study (Möller C et al., JACI 2002; Jacobsen L et al., Allergy 2007) demonstrated that 3 years of pollen SCIT prevented asthma development at 10-year follow-up with a longitudinal OR of 4.6 (95% CI 1.5–13.7) — the strongest disease-modifying evidence available for any allergy treatment in children. This asthma-prevention finding is specific to monosensitized children; polysensitized children with established asthma follow the same criteria as adults.
What is the best allergy shot for dust mite asthma?
House dust mite (HDM) allergy is one of the best-evidenced SCIT indications for allergic asthma. FDA-standardized Dermatophagoides pteronyssinus and D. farinae extracts are available from multiple US manufacturers. For patients aged 5–65 (per the 2025 label revision), Odactra is the FDA-approved sublingual immunotherapy tablet for HDM-driven allergic rhinitis and asthma — the only FDA-approved SLIT option for this allergen class. For polysensitized patients with HDM plus additional allergens, compounded SCIT is the standard approach; Curex provides at-home SCIT for eligible well-controlled asthmatic patients at $129/month, with allergist oversight and Zoom-supervised dosing. An allergist will confirm which HDM species and which additional allergens are driving symptoms before prescribing.
Will allergy shots cure my asthma?
No treatment for asthma should be characterized as a cure, including SCIT. The Cochrane review (Abramson 2010) documents significant reductions in asthma symptoms and medication use — roughly one-third reductions across the studies — but not complete disease elimination. SCIT induces allergen-specific immune tolerance: the immune system becomes less reactive to the treated allergen over time, reducing allergen-driven asthma triggers specifically. Non-allergic asthma triggers (exercise, cold air, pollution, infections) are not addressed by SCIT. The strongest claim supported by the evidence is that 3–5 years of SCIT can produce durable reduction in allergen-driven asthma burden for years after stopping, per the disease-modifying mechanism established in Durham 1999 (NEJM) and the PAT pediatric data.
Related Articles
Allergy Shots: The Complete Patient Guide to SCIT | Curex
Allergy shots (SCIT) are the only FDA-recognized disease-modifying allergy treatment. Learn who qualifies, how they work, and what alternatives exist.
Read moreCat Allergy Vaccine Explained | Curex SCIT Guide
Cat allergy vaccine means three different things. SCIT uses FDA-standardized Fel d 1 extract for ~72% symptom relief. No one-shot cure exists.
Read moreAllergy Shots for Humans | Curex Complete SCIT Guide
Yes — allergy shots for humans exist. SCIT has Cochrane SMD −0.73, 51 RCTs, and 1 fatality per 23.3M visits. Not Cytopoint. Not Apoquel. Full guide with pet-allergen disambiguation.
Read moreGet your allergy shots — without the clinic.
Curex's flat $129/month covers end-to-end at-home immunotherapy — a personalized serum compounded to USP <797> sterile standards, board-certified allergist oversight, and one weekly injection you give yourself at home. No clinic visits, no facility fees. HSA/FSA eligible.
$129/mo flat · No facility fees · HSA/FSA eligible · Cancel anytime
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.